Clinical trial NCT02204332 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cabazitaxel
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C
Reason stopped: 
    interim analysis performed on the first 10 patients showed no efficacy of cabazitaxel
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have given written informed consent.

          -  Men and women aged ≥ 18 years.

          -  Patients with histologically confirmed metastatic advanced colorectal cancer without
             the possibility of potentially curative treatment.

          -  Patients with a life expectancy more than three months.

          -  Patients with advanced colorectal cancer in progression after receiving standard
             treatment.

          -  Patients with grade 0-2 functional status, according to Eastern Cooperative Oncology
             Group (ECOG).

          -  Patients with evaluable tumor by RECIST criteria.

          -  Patients recovered and with a degree less than or equal to 1, or baseline of all
             important pre-treatment-related AEs (excluding alopecia).

          -  Ability and willingness of the patient to consent to participation in the study.

          -  Ability to understand and comply with study procedures.

        Exclusion Criteria:

          -  Patients with a performance status greater than 2, as Eastern Cooperative Oncology
             Group (ECOG).

          -  Inadequate marrow reserve, within 7 days prior to randomization:

               -  absolute neutrophil count <1.5 x 109 / L

               -  Hemoglobin <9.0 g / dL

               -  Platelet count <100 x 109 / L

          -  Inadequate liver function within 7 days prior to randomization:

               -  AST (SGOT) and ALT (SGPT)> 3.0 x ULN or 5> x ULN in case of abnormal liver
                  function due to underlying liver metastases.

               -  Alkaline phosphatase> 3 × ULN (or 5 times the ULN if due to underlying liver
                  metastases).

               -  Total bilirubin> 1.5 x ULN.

          -  Previous history of other malignancy, except for skin basal or squamous cell cancer
             with proper treatment, or in situ cervical cancer, or other cancers, in which the
             patient has been free of the disease in the last 5 years.

          -  Simultaneous treatment with concomitant anticancer therapy.

          -  History of brain metastases, uncontrolled compression of spinal cord, or carcinomatous
             meningitis, or new evidence of brain or leptomeningeal disease pathologies.

          -  Acquired Immunodeficiency Syndrome (AIDS-related diseases) or human immunodeficiency
             virus (HIV) or conditions requiring antiretroviral therapy virus.

          -  symptomatic grade ≥ 2 peripheral sensory neuropathy, according to NCI-CTCAE v4.0.

          -  Any severe acute or chronic medical condition that may affect the patient's ability to
             participate in the study, or may lead to unacceptable security risks and
             non-compliance with protocol procedures or may interfere with the interpretation of
             the study results.

          -  Pregnant women or who are breastfeeding. Pregnancy assessment will be conducted by a
             test serum or urine during the 7 days prior to randomization.

          -  Patient (male or female) of reproductive age who still disagrees with the use of
             effective contraception during the treatment period and for at least 3 months after
             completion of the treatment period of the study. The definition of "effective method
             of birth control" is the opinion of the investigator.

          -  Participation in another clinical trial with an investigational drug and / or an
             investigational drug as adjunctive therapy within 30 days prior to randomization.

          -  Concomitant treatment with prohibited drugs as potent inhibitors or inducers of
             cytochrome P450 3A4.